3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents

Details for Australian Patent Application No. 2007304365 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Andjelkovic, Mirjana; Panousis, Constantinos G.; Benardeau, Agnes; Roever, Stephan; Nettekoven, Matthias; Chaput, Evelyne; Obst Sander, Ulrike; Hebeisen, Paul

Agent Spruson & Ferguson

Pub. Number AU-A-2007304365

PCT Pub. Number WO2008/040651

Priority 06121755.0 04.10.06 EP

Filing date 24 September 2007

Wipo publication date 10 April 2008

International Classifications

C07D 213/63 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

A61K 31/465 (2006.01) - Nicotine

A61K 31/4965 (2006.01) - Non-condensed pyrazines

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

C07D 213/74 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

C07D 241/24 (2006.01) Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings

Event Publications

23 April 2009 PCT application entered the National Phase

  PCT publication WO2008/040651 Priority application(s): WO2008/040651

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007304380-Alternative fuel injector for dual fuel systems

2007304363-Pyrazine-2-carboxamide derivatives as CB2 receptor modulators